MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-02-2022
1Life Healthcare Revenue 2011-2026 | ONEM
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue 1Life Healthcare
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 623 M | 380 M | 276 M | 213 M | 177 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 623 M | 177 M | 334 M |
Quarterly Revenue 1Life Healthcare
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 261 M | - | 254 M | - | 151 M | 120 M | 121 M | 122 M | 102 M | 78 M | 78.8 M | 77.4 M | 69.6 M | 66.2 M | 63 M | 58 M | 49.8 M | 51.6 M | 53.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 261 M | 49.8 M | 105 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M |  USA |
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B | USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Evolent Health
EVH
|
382 M | $ 2.51 | -0.79 % | $ 235 M | USA |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.23 | 3.72 % | $ 860 M | USA |
 |
SCWorx Corp.
WORX
|
2.88 M | - | - | $ 7.71 M | USA |
 |
Akerna Corp.
KERN
|
185 M | - | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
120 M | - | -0.58 % | $ 51.7 M | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
10x Genomics
TXG
|
619 M | $ 24.8 | 5.17 % | $ 2.91 B | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 6.05 | 2.02 % | $ 104 M | USA |
 |
Health Catalyst
HCAT
|
311 M | $ 1.12 | 5.66 % | $ 78.3 M | USA |
 |
HealthEquity
HQY
|
1.31 B | $ 81.36 | 1.81 % | $ 7.01 B | USA |
 |
Premier
PINC
|
263 M | - | - | $ 2.33 B | USA |
 |
Schrödinger
SDGR
|
256 M | $ 11.91 | 4.02 % | $ 875 M | USA |
 |
Phreesia
PHR
|
481 M | $ 8.6 | 0.47 % | $ 514 M | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
Teladoc Health
TDOC
|
2.53 B | $ 5.24 | 0.38 % | $ 923 M | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
American Well Corporation
AMWL
|
249 M | $ 5.51 | -0.72 % | $ 88.4 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
HealthStream
HSTM
|
292 M | $ 20.34 | -0.15 % | $ 618 M | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 36.33 | 3.77 % | $ 1.67 B | USA |
 |
Progyny
PGNY
|
298 M | $ 17.17 | 1.12 % | $ 1.47 B | USA |
 |
So-Young International
SY
|
-1.52 M | $ 2.76 | 2.6 % | $ 219 M |  China |
 |
Veeva Systems
VEEV
|
3.2 B | $ 159.09 | 0.4 % | $ 26 B | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 1.99 | -1.24 % | $ 6.8 M | China |